Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections.
Identifieur interne : 000717 ( PubMed/Corpus ); précédent : 000716; suivant : 000718Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections.
Auteurs : Kwamena William Coleman Sagoe ; Kwabena Obeng Duedu ; Francesca Ziga ; Afrakoma Adjoa Agyei ; Theophilus Korku Adiku ; Margaret Lartey ; Julius Abraham Addo Mingle ; Max ArensSource :
- Annals of clinical microbiology and antimicrobials [ 1476-0711 ] ; 2016.
English descriptors
- KwdEn :
- Adult, Africa, Western, Antiretroviral Therapy, Highly Active, Antiviral Agents (therapeutic use), CD4 Lymphocyte Count, Coinfection, Female, Genotype, HIV Infections (drug therapy), HIV Infections (immunology), HIV Infections (virology), HIV-1 (drug effects), HIV-1 (genetics), HIV-1 (growth & development), Hepatitis B (drug therapy), Hepatitis B (immunology), Hepatitis B (virology), Hepatitis B virus (drug effects), Hepatitis B virus (genetics), Hepatitis B virus (growth & development), Humans, Longitudinal Studies, Male, Middle Aged, RNA, Viral (antagonists & inhibitors), RNA, Viral (blood), RNA, Viral (genetics), Sex Factors, Treatment Outcome, Viral Load (drug effects).
- MESH :
- chemical , antagonists & inhibitors : RNA, Viral.
- chemical , blood : RNA, Viral.
- chemical , genetics : RNA, Viral.
- chemical , therapeutic use : Antiviral Agents.
- drug effects : HIV-1, Hepatitis B virus, Viral Load.
- drug therapy : HIV Infections, Hepatitis B.
- genetics : HIV-1, Hepatitis B virus.
- growth & development : HIV-1, Hepatitis B virus.
- immunology : HIV Infections, Hepatitis B.
- virology : HIV Infections, Hepatitis B.
- Adult, Africa, Western, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Coinfection, Female, Genotype, Humans, Longitudinal Studies, Male, Middle Aged, Sex Factors, Treatment Outcome.
Abstract
Co-infection of HIV with HBV is common in West Africa but little information is available on the effects of HBV on short-term therapy for HIV patients. A 28 day longitudinal study was conducted to examine short-term antiretroviral therapy (ART) outcomes in HIV infected individuals with HBV co-infection.
DOI: 10.1186/s12941-016-0152-2
PubMed: 27251610
Links to Exploration step
pubmed:27251610Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections.</title><author><name sortKey="Sagoe, Kwamena William Coleman" sort="Sagoe, Kwamena William Coleman" uniqKey="Sagoe K" first="Kwamena William Coleman" last="Sagoe">Kwamena William Coleman Sagoe</name><affiliation><nlm:affiliation>Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana. ksagoe@ug.edu.gh.</nlm:affiliation></affiliation></author><author><name sortKey="Duedu, Kwabena Obeng" sort="Duedu, Kwabena Obeng" uniqKey="Duedu K" first="Kwabena Obeng" last="Duedu">Kwabena Obeng Duedu</name><affiliation><nlm:affiliation>Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name><affiliation><nlm:affiliation>Pharmacy Department, Korle-Bu Teaching Hospital, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Agyei, Afrakoma Adjoa" sort="Agyei, Afrakoma Adjoa" uniqKey="Agyei A" first="Afrakoma Adjoa" last="Agyei">Afrakoma Adjoa Agyei</name><affiliation><nlm:affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, University of Ghana, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Adiku, Theophilus Korku" sort="Adiku, Theophilus Korku" uniqKey="Adiku T" first="Theophilus Korku" last="Adiku">Theophilus Korku Adiku</name><affiliation><nlm:affiliation>Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation><nlm:affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, University of Ghana, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Mingle, Julius Abraham Addo" sort="Mingle, Julius Abraham Addo" uniqKey="Mingle J" first="Julius Abraham Addo" last="Mingle">Julius Abraham Addo Mingle</name><affiliation><nlm:affiliation>Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Arens, Max" sort="Arens, Max" uniqKey="Arens M" first="Max" last="Arens">Max Arens</name><affiliation><nlm:affiliation>Retrovirus Laboratory, Department of Pediatrics, Washington University Medical School, St. Louis, MO, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27251610</idno><idno type="pmid">27251610</idno><idno type="doi">10.1186/s12941-016-0152-2</idno><idno type="wicri:Area/PubMed/Corpus">000717</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000717</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections.</title><author><name sortKey="Sagoe, Kwamena William Coleman" sort="Sagoe, Kwamena William Coleman" uniqKey="Sagoe K" first="Kwamena William Coleman" last="Sagoe">Kwamena William Coleman Sagoe</name><affiliation><nlm:affiliation>Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana. ksagoe@ug.edu.gh.</nlm:affiliation></affiliation></author><author><name sortKey="Duedu, Kwabena Obeng" sort="Duedu, Kwabena Obeng" uniqKey="Duedu K" first="Kwabena Obeng" last="Duedu">Kwabena Obeng Duedu</name><affiliation><nlm:affiliation>Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Ziga, Francesca" sort="Ziga, Francesca" uniqKey="Ziga F" first="Francesca" last="Ziga">Francesca Ziga</name><affiliation><nlm:affiliation>Pharmacy Department, Korle-Bu Teaching Hospital, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Agyei, Afrakoma Adjoa" sort="Agyei, Afrakoma Adjoa" uniqKey="Agyei A" first="Afrakoma Adjoa" last="Agyei">Afrakoma Adjoa Agyei</name><affiliation><nlm:affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, University of Ghana, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Adiku, Theophilus Korku" sort="Adiku, Theophilus Korku" uniqKey="Adiku T" first="Theophilus Korku" last="Adiku">Theophilus Korku Adiku</name><affiliation><nlm:affiliation>Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Lartey, Margaret" sort="Lartey, Margaret" uniqKey="Lartey M" first="Margaret" last="Lartey">Margaret Lartey</name><affiliation><nlm:affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, University of Ghana, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Mingle, Julius Abraham Addo" sort="Mingle, Julius Abraham Addo" uniqKey="Mingle J" first="Julius Abraham Addo" last="Mingle">Julius Abraham Addo Mingle</name><affiliation><nlm:affiliation>Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Arens, Max" sort="Arens, Max" uniqKey="Arens M" first="Max" last="Arens">Max Arens</name><affiliation><nlm:affiliation>Retrovirus Laboratory, Department of Pediatrics, Washington University Medical School, St. Louis, MO, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Annals of clinical microbiology and antimicrobials</title><idno type="eISSN">1476-0711</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Africa, Western</term><term>Antiretroviral Therapy, Highly Active</term><term>Antiviral Agents (therapeutic use)</term><term>CD4 Lymphocyte Count</term><term>Coinfection</term><term>Female</term><term>Genotype</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (immunology)</term><term>HIV Infections (virology)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (genetics)</term><term>HIV-1 (growth & development)</term><term>Hepatitis B (drug therapy)</term><term>Hepatitis B (immunology)</term><term>Hepatitis B (virology)</term><term>Hepatitis B virus (drug effects)</term><term>Hepatitis B virus (genetics)</term><term>Hepatitis B virus (growth & development)</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>RNA, Viral (antagonists & inhibitors)</term><term>RNA, Viral (blood)</term><term>RNA, Viral (genetics)</term><term>Sex Factors</term><term>Treatment Outcome</term><term>Viral Load (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>Hepatitis B virus</term><term>Viral Load</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>HIV-1</term><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Africa, Western</term><term>Antiretroviral Therapy, Highly Active</term><term>CD4 Lymphocyte Count</term><term>Coinfection</term><term>Female</term><term>Genotype</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Sex Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Co-infection of HIV with HBV is common in West Africa but little information is available on the effects of HBV on short-term therapy for HIV patients. A 28 day longitudinal study was conducted to examine short-term antiretroviral therapy (ART) outcomes in HIV infected individuals with HBV co-infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27251610</PMID><DateCreated><Year>2016</Year><Month>06</Month><Day>02</Day></DateCreated><DateCompleted><Year>2017</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1476-0711</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jun</Month><Day>02</Day></PubDate></JournalIssue><Title>Annals of clinical microbiology and antimicrobials</Title><ISOAbbreviation>Ann. Clin. Microbiol. Antimicrob.</ISOAbbreviation></Journal><ArticleTitle>Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections.</ArticleTitle><Pagination><MedlinePgn>38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12941-016-0152-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Co-infection of HIV with HBV is common in West Africa but little information is available on the effects of HBV on short-term therapy for HIV patients. A 28 day longitudinal study was conducted to examine short-term antiretroviral therapy (ART) outcomes in HIV infected individuals with HBV co-infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Plasma from 18 HIV infected individuals co-infected with HBV and matched controls with only HIV infection were obtained at initiation, and 7 and 28 days after ART. HIV-1 viral load changes were monitored. Clinical and demographic data were also obtained from patient folders, and HIV-1 drug resistance mutation and subtype analysis performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The presence of HBV co-infection did not significantly affect HIV-1 viral load changes within 7 or 28 days. The CD4(+) counts on the other hand of patients significantly affected the magnitude of HIV-1 viral load decline after 7 days (ρ = -0.441, p = 0.040), while the pre-ART HIV-1 VL (ρ = 0.844, p = <0.001) and sex (U = 19.0, p = 0.020) also determined HIV-1 viral load outcomes after 28 days of ART. Even though the geometric sensitivity score of HIV-1 strains were influenced by the HIV-1 subtypes (U = 56.00; p = 0.036), it was not a confounder for ART outcomes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There may be the need to consider the confounder effects of sex, pre-ART CD4(+), and pre-ART HIV-1 viral load in the discourse on HIV and HBV co-infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sagoe</LastName><ForeName>Kwamena William Coleman</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana. ksagoe@ug.edu.gh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duedu</LastName><ForeName>Kwabena Obeng</ForeName><Initials>KO</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, School of Basic and Biomedical Sciences, University of Health & Allied Sciences, Ho, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziga</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pharmacy Department, Korle-Bu Teaching Hospital, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agyei</LastName><ForeName>Afrakoma Adjoa</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adiku</LastName><ForeName>Theophilus Korku</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lartey</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine and Therapeutics, School of Medicine and Dentistry, University of Ghana, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mingle</LastName><ForeName>Julius Abraham Addo</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology, School of Biomedical and Allied Health Sciences, University of Ghana, Korle-Bu, P. O. Box KB173, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arens</LastName><ForeName>Max</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Retrovirus Laboratory, Department of Pediatrics, Washington University Medical School, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Clin Microbiol Antimicrob</MedlineTA><NlmUniqueID>101152152</NlmUniqueID><ISSNLinking>1476-0711</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2001 May 15;183(10):1455-65</RefSource><PMID Version="1">11319681</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Aug 19;8(8):e71972</RefSource><PMID Version="1">23977189</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2011 Nov 28;25(18):2269-78</RefSource><PMID Version="1">21941167</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol. 1989 Jun;63(6):2857-60</RefSource><PMID Version="1">2724417</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>World J Gastroenterol. 2013 Mar 14;19(10):1602-10</RefSource><PMID Version="1">23538773</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2004 May 15;38(10):1471-7</RefSource><PMID Version="1">15156487</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>HIV Med. 2008 May;9(5):300-6</RefSource><PMID Version="1">18400077</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2001 Jan 5;15(1):47-54</RefSource><PMID Version="1">11192867</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2001 Nov 24;358(9295):1760-5</RefSource><PMID Version="1">11734232</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Aug 12;8(8):e64345</RefSource><PMID Version="1">23950859</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):599-606</RefSource><PMID Version="1">18645511</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2004 Jun;73(2):158-66</RefSource><PMID Version="1">15122787</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2008 Dec 1;47(11):1479-85</RefSource><PMID Version="1">18937580</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2012 Mar 9;30(12):2212-9</RefSource><PMID Version="1">22273662</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2004 May 21;18(8):1169-77</RefSource><PMID Version="1">15166532</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Virol. 2012 Oct;2(5):636-43</RefSource><PMID Version="1">23006584</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2010 Sep;48(9):3223-30</RefSource><PMID Version="1">20631103</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2009 Oct 15;49(8):1268-73</RefSource><PMID Version="1">19772386</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2004 Sep;74(1):34-40</RefSource><PMID Version="1">15258966</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Virol. 2007 Oct;40(2):163-7</RefSource><PMID Version="1">17827059</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Virol Methods. 2006 May;133(2):137-45</RefSource><PMID Version="1">16375980</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1999 Feb 25;13(3):429-30</RefSource><PMID Version="1">10199240</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Virol J. 2009 Feb 26;6:27</RefSource><PMID Version="1">19245688</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(2):e57580</RefSource><PMID Version="1">23437399</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr HIV Res. 2008 Jan;6(1):43-8</RefSource><PMID Version="1">18288974</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2012 Jan;84(1):6-10</RefSource><PMID Version="1">22095533</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2013 Nov 1;208(9):1454-8</RefSource><PMID Version="1">23901088</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Med Virol. 2008 Aug;80(8):1332-6</RefSource><PMID Version="1">18551596</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2003 Mar 15;187(6):896-900</RefSource><PMID Version="1">12660935</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2005 Mar 25;19(5):463-71</RefSource><PMID Version="1">15764851</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2012 Dec;67(12):2939-42</RefSource><PMID Version="1">22915461</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1989 Jul;86(13):5168-72</RefSource><PMID Version="1">2740349</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2004 Feb 15;189(4):593-601</RefSource><PMID Version="1">14767811</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2005 Mar 24;19(6):593-601</RefSource><PMID Version="1">15802978</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):197-205</RefSource><PMID Version="1">24694929</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1999 Oct 1;13(14):1873-80</RefSource><PMID Version="1">10513645</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Intern Med. 2002 Oct 14;162(18):2125-32</RefSource><PMID Version="1">12374521</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):280-9</RefSource><PMID Version="1">19521248</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000354" MajorTopicYN="N">Africa, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023241" MajorTopicYN="N">Antiretroviral Therapy, Highly Active</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006515" MajorTopicYN="N">Hepatitis B virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth & development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4890471</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiretroviral therapy</Keyword><Keyword MajorTopicYN="N">Co-infection</Keyword><Keyword MajorTopicYN="N">Drug resistance</Keyword><Keyword MajorTopicYN="N">Hepatitis B virus</Keyword><Keyword MajorTopicYN="N">Human immunodeficiency virus</Keyword><Keyword MajorTopicYN="N">Short-term therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>05</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27251610</ArticleId><ArticleId IdType="doi">10.1186/s12941-016-0152-2</ArticleId><ArticleId IdType="pii">10.1186/s12941-016-0152-2</ArticleId><ArticleId IdType="pmc">PMC4890471</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000717 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000717 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27251610
|texte= Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27251610" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |